Hospitals across the country have been told to stop using an angiography catheter after the manufacturer determined the devices were built outside their approved design specification. The Food and Drug Administration issued an early alert on August 28 covering Boston Scientific's Imager II Angiographic Catheters, and the company is removing them from the market and discontinuing the product line.
The defect is in the tip. Boston Scientific determined the catheters were manufactured with reduced levels of stabilizing agents in the tips, which may increase the risk that a tip degrades and detaches during use.
The alert also contains a detail that should shape how patients read it. According to the FDA notice, no increase in tip detachment complaints has been identified for the affected lots. The devices are being removed because they were made outside specification, not because a wave of injuries prompted it. The agency does report that as of July 16, the company had reported two serious injuries and no deaths associated with the issue.
The Difference Between a Delay and an Embolism
The agency's description of consequences separates the common from the severe, and the gap between them is wide.
The most common adverse health consequence of a tip detaching inside a blood vessel, with a likelihood the FDA describes as occurring every time it happens, is a delay in the procedure while the team exchanges the device for a new one. That is the realistic scenario in most cases.
The most serious potential consequence, which the agency characterizes as remote, is a life-threatening embolism caused by a device fragment obstructing blood flow and leading to end-organ failure. Retrieving a fragment can require additional intervention.
Imager II catheters are sterile, single-use diagnostic devices used to create images of the peripheral vasculature, the arteries and veins outside the heart and brain. Interventional cardiologists, vascular surgeons and interventional radiologists use them during diagnostic angiography, and they come in a range of shapes and lengths.
Inventory Is the Weak Point in This Removal
Boston Scientific sent affected customers a letter on August 24 telling them to immediately stop further use or distribution, segregate affected product, continue standard-of-care monitoring for patients already treated, verify inventory against the list of affected devices, return the product, and complete a verification tracking form.
The alert flags a specific operational hazard that hospital staff will recognize. Facilities often remove products from the outer carton and store them in the inner pouch alone, and the UPN codes on inner and outer labeling are different. A supply technician checking only one set of codes could miss affected stock sitting on a shelf. Because the catheters are sold in five-packs, the company also asked facilities to report individual units rather than cartons.
That is a small procedural detail with real consequences, because a removal only works if every unit is found. MedicalDaily has reported on a cascade of kit recalls this month in which a single recalled component reached thousands of American hospitals through convenience kits, a pattern driven by the same problem of tracking parts once they leave their original packaging.
Early alerts are a relatively new federal tool. The agency issues an early alert to notify the public of a potentially high-risk device issue while it is still reviewing the information, before it has formally classified the action.
Patients Who Already Had the Procedure
The guidance for someone who underwent a peripheral angiogram in recent months is deliberately undramatic, and it should stay that way.
Boston Scientific instructed clinicians to continue following the standard of care when monitoring patients treated with the product. That is not a directive for patients to seek follow-up imaging or call for a scan. A tip detachment is something an interventional team would identify during the procedure, not something that surfaces silently weeks later.
Anyone with a genuine concern can ask the facility that performed their procedure whether Imager II catheters were used and whether anything unexpected occurred. Symptoms that would warrant prompt evaluation after any vascular procedure are the usual ones: new or worsening pain, coldness, numbness or color change in a limb, or swelling and bleeding at the access site. Those signs are far more commonly caused by ordinary post-procedure complications than by a retained fragment.
This article provides general information and is not a diagnosis. Nobody should delay scheduled vascular care because of this alert. Alternative angiographic catheters from other manufacturers remain widely available, and the procedures these devices support are not being suspended.
An Unusual Ending for a Product Line
Several things about this action are still open.
The FDA has not classified the removal, so the formal recall class has not been assigned. The agency has not published the number of devices involved or how long the out-of-specification manufacturing continued. Beyond the two serious injuries reported as of mid-July, no further injury reports have been made public.
The company's decision to discontinue the product entirely rather than correct the manufacturing problem is notable. Boston Scientific has not publicly explained that choice, and a discontinuation is a commercial decision that does not by itself indicate a broader safety finding.
Customers in the United States with questions, quality problems, or adverse reactions are directed to contact Boston Scientific through the complaints address listed in the alert. Clinicians and patients can report device problems through MedWatch, and the agency posts updates on its device recalls and early alerts page. MedicalDaily will report the recall classification when the FDA assigns it, and any further injury reports tied to the affected lots.
Key Questions Answered
What is being removed? Boston Scientific Imager II Angiographic Catheters, used to image the peripheral vasculature. The company is also discontinuing the product.
Why? The catheters were manufactured with reduced levels of stabilizing agents in the tips, which may increase the risk of tip degradation and detachment.
Have patients been hurt? The FDA says two serious injuries and no deaths have been reported in connection with the issue, though no increase in tip detachment complaints was found for the affected lots.
What could happen if a tip detached? Most commonly, a procedure delay while the device is exchanged. The most serious potential consequence, described as remote, is a life-threatening embolism.
Should patients who had a procedure do anything? The company advises clinicians to continue standard-of-care monitoring. There is no instruction for patients to seek additional imaging.
When should someone seek care after a vascular procedure? New or worsening limb pain, coldness, numbness or color change, or swelling and bleeding at the access site.
Is this a formal recall? Not yet classified. Early alerts notify the public of a potentially high-risk device issue while the agency is still reviewing it.
